

Blue Gem Hemp Publishes a White Paper for Clinicians

Full Spectrum CBD Oil and Diabetes White Paper.

DEERFIELD, ILLINOIS, UNITED STATES, March 13, 2023 /EINPresswire.com/ -- Blue Gem Hemp publishes a white paper highlighting the potential benefits of [Full Spectrum CBD Oil](#) for [Diabetes](#).

<https://www.bluegemhemp.com/blogs/news/full-spectrum-cbd-oil-and-diabetes>

"The more we learn. The Less we know. Says, Rudaba Naqvi. The CEO of Blue Gem Hemp."

Their series of white paper are written by the clinician for the [clinicians](#) globally, to learn the potential therapeutic effects of Full Spectrum Hemp CBD Oil.

<https://www.bluegemhemp.com/blogs/news>

“

Research and Innovation is ingrained in our DNA. Your Wellness. Our Passion.”

Rudaba Naqvi

Almost half a billion people are living with diabetes worldwide, and the prevalence is projected to increase to 25% in 2030 and 51% in 2045 [1]. A growing body of scientific evidence links endocannabinoid system imbalances to metabolic regulation and glycemic control, generating increased interest in the endocannabinoid

system as a potential drug development target for diabetes [2]. Additionally, the endocannabinoid system modulates pathophysiological processes related to the development of diabetic complications, such as retinopathy, cardiovascular disease, nephropathy, and peripheral



neuropathy. Preliminary evidence shows that the antioxidant and anti-inflammatory properties of cannabinoids, such as cannabidiol (CBD) and tetrahydrocannabivarin (THCV), may be beneficial in the treatment of diabetes and its complications [3].

DIABETES AND THE ENDOCANNABINOID SYSTEM

Cannabinoid receptor 1 (CB1R) signaling plays a role in the progression of diabetes and its complications, suggesting that the endocannabinoid system may be a promising therapeutic target. Patients with type 2 diabetes have higher serum levels of endocannabinoids anandamide (N-arachidonylethanolamine; AEA) and 2-arachidonoylglycerol (2-AG) compared to healthy volunteers. CB1R receptors are found on pancreatic islet cells, but the exact role in diabetes pathogenesis is unclear [3].



Blue Gem Full-Spectrum CBD Oil

Rimonabant is a synthetic CB1R antagonist that showed substantial potential for the treatment of diabetes, but it was removed from the market in 2008 due to severe psychiatric side effects, including anxiety, depression, and suicidality [4], [5]. Evidence from rimonabant trials showed that CB1R modulation led to significant reductions in body weight, waist circumference, and HbA1c in patients with type 2 diabetes [6].

PHYTOCANNABINOIDS AND DIABETES

Phytocannabinoids such as CBD and THCV are produced naturally by cannabis plants. They exhibit antagonistic activity on CB1R signaling but do not appear to have the psychiatric risks associated with rimonabant. In addition to these phytocannabinoids, hemp or cannabis plants produce several other cannabinoids, terpenes, and flavonoids with therapeutic potential in the treatment of diabetes.

<https://www.bluegemhemp.com/blogs/news/full-spectrum-cbd-oil-and-diabetes>

David Nordwell - Lead PR Associate
Blue Gem Hemp
+1 8473126222
Info@bluegemhemp.com

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[TikTok](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/621933538>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.